RE: #sng #WHO1 Apr 2020 16:30
Great to see, but this doesnt read so well or is it just me?
Asthma phase II trial:
Djukanovic et al. Am J Respir
Crit Care Med. 2014.190(2)
:145-54 ;
NCT01126177
Asthma: Phase II trials
(SG005 and INEXAS) in
asthma, conducted by
Synairgen (NCT01126177)
and AstraZeneca
respectively, suggest that
SNG001 boosts antiviral
responses in the lungs, has a
beneficial effect on lung
function and, in more
difficult to treat patients,
improves asthma control
during cold infections.
However, the unexpectedly
low exacerbation rate (<10%)
in the INEXAS trial population
suggests that the economic
viability of the drug in an
asthma indication would be
limited.
(https://www.synairgen.com
/programmes/ifn-%CE%B2-
in-copd/)